NCT04342429 Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
| NCT ID | NCT04342429 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Small-cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-03-19 |
| Primary Completion | 2026-05-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-03-19 with a primary completion date of 2026-05-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed small cell lung cancer, limited or extensive stage. * Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist. * Age 18 or greater Exclusion Criteria: * Prior radiation therapy which would provide significant dose overlap with the planned target volume(s) * Pregnancy
Contact & Investigator
Kristin Higgins, MD
PRINCIPAL INVESTIGATOR
Emory University-Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT04342429 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small-cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04342429 currently recruiting?
Yes, NCT04342429 is actively recruiting participants. Contact the research team at kristin.higgins@emory.edu for enrollment information.
Where is the NCT04342429 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT04342429 clinical trial?
NCT04342429 is sponsored by Emory University. The principal investigator is Kristin Higgins, MD at Emory University-Winship Cancer Institute. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.